MOST POPULAR

Roche announces details of its ‘pivotal’ huntingtin-lowering study

The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease t’s a time of huge developments in the...

Roche announces details of its ‘pivotal’ huntingtin-lowering study

The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease t’s a time of huge developments in the...

New £9.1m contract with a top 10 global pharmaceutical company

Specialist medical imaging services for a Phase III Huntington’s disease clinical trial, highlighting the value of IXICO’s data science expertise in neuroscience drug development. IXICO...

PEOPLE

LIFE

DESIGN

[td_block_social_counter facebook=”envato” twitter=”envato” youtube=”envato”]

LATEST VIDEOS

- Advertisement -

TECH POPULAR

TRAVEL

Benitec Biopharma cross-licenses with uniQure to treat Huntington’s and Hepatitis B

Sydney, Tuesday December 4, 2012. Benitec Biopharma Ltd (ASX: BLT) is pleased to announce that it has entered into a sub-licensing agreement with Amsterdam-based uniQure...
Print Friendly, PDF & Email
0 Condivisioni